Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides|
|Abstract:||The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.|
|Inventor(s):||von Borstel; Reid W. (Potomac, MD), Bamat; Michael K. (Potomac, MD)|
|Assignee:||Wellstat Therapeutics Corporation (Gaithersburg, MD)|
|Filing Date:||Jun 07, 1995|
|Claims:||1. A composition comprising an acyl derivative of uridine; and a compound capable of inhibiting uridine phosphorylase. |
2. A composition as in claim 1 wherein said inhibitor of uridine phosphorylase is selected from the group consisting of benzylacyclouridine, benzyloxybenzylacyclo-uridine, aminomethyl-benzylacyclouridine, aminomethyl-benzyloxybenzylacyclouridine, hydroxymethyl-benzylacyclouridine, hydroxymethyl-benzyloxybenzyl-acyclouridine, 2,2'-anhydro-5-ethyluridine, 5-benzyl barbiturate, 5-benzyloxybenzyl barbiturate, 5-benzyloxybenzyl-1-[(1-hydroxy-2-ethoxy)methyl]barbiturate, 5-benzyloxybenzylacetyl-1-[(1-hydroxy-2-ethoxy)methyl]barbiturate, and 5-methoxybenzylacetylacyclobarbiturate.
3. A composition comprising: an acyl derivative of cytidine or deoxycytidine; and a compound capable of inhibiting deoxycytidine deaminase.
4. A composition as in claim 3 wherein said inhibitor of cytidine deaminase is selected from the group consisting of tetrahydrouridine or tetrahydro-2'-deoxyuridine.